NeuroPace Inc (NPCE) stock

NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/3013% above fair value

$7.56−4.46 (-37.10%)

Close on Nov 13, 2026Market cap $259.49MP/E –Yield 0.00%

NeuroPace total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

NeuroPace's total debt was $59.16M at Sep 30, 2026. For fiscal 2025 it was $58.88M, down 1.1% from the year before. The highest annual figure on record is $59.53M in fiscal 2024.

Annual total debt

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$58.88M	-1.1%
FY2024	Dec 31, 2024	$59.53M	+4.5%
FY2023	Dec 31, 2023	$56.95M	+7.6%
FY2022	Dec 31, 2022	$52.91M	+6.2%
FY2021	Dec 31, 2021	$49.85M	-5.7%
FY2020	Dec 31, 2020	$52.86M	–

Quarterly total debt

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$59.16M	+0.7%
Q2 FY2026	Jun 30, 2026	$59.01M	+0.7%
Q1 FY2026	Mar 31, 2026	$59.02M	-1.3%
Q4 FY2025	Dec 31, 2025	$58.88M	-1.1%
Q3 FY2025	Sep 30, 2025	$58.75M	-0.9%
Q2 FY2025	Jun 30, 2025	$58.62M	-0.7%
Q1 FY2025	Mar 31, 2025	$59.79M	+3.0%
Q4 FY2024	Dec 31, 2024	$59.53M	+4.5%
Q3 FY2024	Sep 30, 2024	$59.27M	+6.0%
Q2 FY2024	Jun 30, 2024	$59.02M	+7.6%
Q1 FY2024	Mar 31, 2024	$58.04M	+7.8%
Q4 FY2023	Dec 31, 2023	$56.95M	+7.6%
Q3 FY2023	Sep 30, 2023	$55.89M	+7.6%
Q2 FY2023	Jun 30, 2023	$54.85M	+7.5%
Q1 FY2023	Mar 31, 2023	$53.86M	+7.5%
Q4 FY2022	Dec 31, 2022	$52.91M	+6.2%
Q3 FY2022	Sep 30, 2022	$51.95M	+4.8%
Q2 FY2022	Jun 30, 2022	$51.02M	+3.4%
Q1 FY2022	Mar 31, 2022	$50.12M	-5.7%
Q4 FY2021	Dec 31, 2021	$49.85M	-5.7%
Q3 FY2021	Sep 30, 2021	$49.58M	–
Q2 FY2021	Jun 30, 2021	$49.35M	–
Q1 FY2021	Mar 31, 2021	$53.15M	–
Q4 FY2020	Dec 31, 2020	$52.86M	–